Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,637,512

« Back to Dashboard
Patent 8,637,512 protects LAMICTAL XR and is included in one NDA. There has been one Paragraph IV challenge on Lamictal XR. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has forty patent family members in thirty countries.

Summary for Patent: 8,637,512

Title:Formulations and method of treatment
Abstract: A sustained release formulation of lamotrigine or a pharmaceutically acceptable derivative thereof and methods of treatment and uses thereof.
Inventor(s): Buxton; Ian Richard (Mississauga, CA), Karolak; Wlodzimierz (Mississauga, CA), Maleki; Mehran (Mississauga, CA), Iyer; Vijay Mohan (Mississauga, CA)
Assignee: Glaxo Group Limited (Brentford, Middlesex, GB)
Application Number:10/726,752
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 79th percentile
Forward Citations: 1st percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Glaxosmithkline Llc
TABLET, EXTENDED RELEASE;ORAL022115-001May 29, 2009RXYesNo8,637,512► subscribeY
Glaxosmithkline Llc
TABLET, EXTENDED RELEASE;ORAL022115-002May 29, 2009RXYesYes8,637,512► subscribeY
Glaxosmithkline Llc
TABLET, EXTENDED RELEASE;ORAL022115-003May 29, 2009RXYesNo8,637,512► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,637,512

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0217492.8Jul 29, 2002
United Kingdom0217493.6Jul 29, 2002
United Kingdom0313801.3Jun 13, 2003

International Patent Family for Patent: 8,637,512

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation2005105353► subscribe
Portugal1524981► subscribe
Poland213565► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.